Advance ZincTek (ASX:ANO) said its managing director and management are "hopeful" that its zinc oxide products are unlikely to be impacted by the new US tariff regime, according to a Friday Australian bourse filing.

Its managing director and management completed an initial review of the pronouncements made by the US Presidential Administration of the imposition of a 100% tariff on imports of branded or patented pharmaceutical products from Oct. 1

Its zinc oxide products are considered active pharmaceutical ingredients but are not branded or patented in the context of these tariffs, the firm noted. It received guidance from trade advisors that its zinc oxide products, along with other active pharmaceutical ingredients, have been historically excluded from similar tariffs.

It added that it maintains a strategic inventory position in the United States, holding over 18 months of supply either in-country or in transit.